Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the final dataset from the Phase 3 short-term clinical trial of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.  The Zerenex data was presented earlier today at the National Kidney Foundation Spring Clinical Meetings being held in Las Vegas, Nevada, in an oral presentation by David S. Goldfarb, M.D., Clinical Chief of Nephrology, NYU Langone Medical Center, Professor of Medicine & Physiology, NYU School of Medicine.  On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.

Phase 3 short-term study designThis Phase 3 study was a multicenter, randomized, open-label trial with a two-week washout period, following which patients were randomized 1:1:1 to receive a fixed dose of Zerenex of either 1 gram, 6 grams or 8 grams per day for a treatment period of 28 days. Zerenex was administered using a 1 gram oral caplet formulation, hence, the fixed-dose arms of 1 gram, 6 grams and 8 grams per day represent 1, 6 and 8 pills per day, respectively.

One hundred fifty-one dialysis patients were enrolled into the study. The Intent-to-Treat (ITT) group included 146 patients, representing all patients who took at least one dose of Zerenex and provided a Baseline (at the end of washout) and at least one post-Baseline efficacy assessment. Efficacy assessments were taken weekly starting at Baseline and subsequently at days 7, 14, 21 and 28.

EFFICACY DATA ANALYSESThe primary endpoint of the study was to determine whether there was a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.

The study met the primary endp
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as the ... Phase 2 award from the Army Corps of Engineers.  ... that kills all biological contaminants and destroys VOCs and ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , ... , ... series documenting,simple protocols for culturing cells in a BioFlo 110,benchtop ... impellers,and control modules to enable growth of a wide variety,of cultures, including ...
... Olive, Ph.D. , Molecular Biology Department , ... Lincoln, NE 68504 , , ... , Optical imaging is ... of a living animal. While several optical imaging modalities employing,fluorescent proteins or bioluminescent reporter ...
... , ... , , ... HPLC by utilizing the Prominence,hardware series. In this respect, we are ... while providing high,reliability and expandability not available with other fast,LC systems., ...
Cached Biology Technology:Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 2Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 3Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 4Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 5Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor 6Near Infrared Technology and Optical Agents For Molecular Imaging 2Near Infrared Technology and Optical Agents For Molecular Imaging 3Near Infrared Technology and Optical Agents For Molecular Imaging 4Near Infrared Technology and Optical Agents For Molecular Imaging 5Near Infrared Technology and Optical Agents For Molecular Imaging 6Near Infrared Technology and Optical Agents For Molecular Imaging 7Prominence UFLC 2Prominence UFLC 3Prominence UFLC 4Prominence UFLC 5Prominence UFLC 6Prominence UFLC 7Prominence UFLC 8
(Date:4/22/2014)... (FASEB) has released updated factsheets for fiscal ... Institutes of Health (NIH) benefits each of the 50 ... make these factsheets available to help citizens and policymakers ... FASEB President, Margaret K. Offermann, MD, PhD. NIH is ... investing $29.2 billion in FY 2013 in medical research, ...
(Date:4/22/2014)... Analyzing thousands of breeding bird surveys sent in ... Canada over 35 years, wildlife researchers report that most ... northward or toward higher elevation in response to climate ... means that most previous studies of potential climate change ... or the other have likely underestimated the effects of ...
(Date:4/22/2014)... French . , ... complete genome and subsequent phylogenetic analysis show that the ... is distinct from strains previously identified in the Democratic ... linked the laboratory confirmed cases with the initial deaths ... is a lethal, highly contagious virus for which there ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
... work. Biology researchers at Lewis & Clark College and ... ancient transfer of a toxin between ancestors of two ... remains as how the toxin passed between the two ... journal Bioinformatics, 22(3): 264-268, in an article titled "Lateral ...
... marijuana or its active cannabinoid ingredient alleviates symptoms ... researchers have found that the brain's natural "endocannabinoids" ... to alleviate neuronal damage. However, scientists have not ... own immune system. , Now, experiments by Oliver ...
... Research Associate at the Stowers Institute for Medical Research, ... investigator with the Howard Hughes Medical Institute, have demonstrated ... is expressed in a cyclic fashion during the formation ... embryo. , The findings, which were published in ...
Cached Biology News:Evolution mystery: Spider venom and bacteria share same toxin 2Brain's own cannabis compound protects against inflammation 2Stowers scientists demonstrate mechanism of vertebral formation 2
... White lyophilized solid. PROTECT FROM LIGHT. ... inhibitor of γ-secretase. Equipotently inhibits the release ... = 2.6 μM) and Aβ x-42 ... HEK293 cells stably transfected with the Amyloid ...
...
Corticoliberin...
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
Biology Products: